Annovis Bio ANVS 深 滬
等待開盤 12-12 09:30:00 美东时间
3.79
-0.410
-9.76%
華盛通- 最 高4.1479
- 今 開4.12
- 成交量 148.69万股
- 最 低 3.70
- 昨 收 4.20
- 總市值 7385.27万
- 52周最高 5.60
- 市盈率 靜 --
- 換手率 7.63%
- 52周最低 1.11
- 委 比 4.71%
- 總股本 1948.62万
- 歷史最高 132.00
- 量 比 2.10
- 振 幅 10.66%
- 歷史最低 1.11
- 每 手 1
- 風險率 1.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's
AC Immune reports Phase 2 data showing stabilized Parkinson's biomarkers, strong antibody response, and a potential slowing of disease progression in early-stage patients.
今天 01:47
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
<p>Annovis Bio, a company developing treatments for neurodegenerative diseases, announced its participation in the 2025 Parkinson Study Group Annual Meeting in San Diego, where it will present data on its drug, buntanetap. The presentation will highlight recent Phase 3 findings showing that buntanetap counteracts cognitive decline and reduces tau biomarkers in Parkinson’s disease patients with amyloid co-pathology. Additionally, cross-study compa...
12-03 13:00
美股牛股 | 绩优股集体大爆发！柯尔百货暴涨超42%，连续两季度上调业绩指引；Symbotic大涨近40%
绩优股集体大爆发！柯尔百货暴涨超42%，连续两季度上调业绩指引；Symbotic大涨近40%，年内涨幅达226%>>
11-26 16:15
Annovis Announces Two Presentations at the CTAD 2025 Conference
Annovis Bio, Inc. will present two studies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) conference in San Diego. The presentations will focus on buntanetap, a potential disease-modifying therapy for Alzheimer's and Parkinson's diseases. Presentation P073 by Cheng Fang, Ph.D., will discuss amyloid co-pathology and cognitive decline in Parkinson's dementia patients treated with buntanetap, while Presentation P007 by Maria Maccecchini, ...
11-24 13:00
Annovis Bio Data From Phase 3 Trila In Early Parkinson's Demonstrates Buntanetap Halted Cognitive Decline Across Overall Patient Count
Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's
11-17 21:01
Annovis Bio GAAP EPS of -$0.37
Annovis Bio press release (ANVS): Q3 GAAP EPS of -$0.37. Annovis’ cash and cash equivalents totaled $15.3 million as of September 30, 2025, compared to $10.6 million as of December 31, 2024. More on A...
11-12 22:18
Annovis Bio Q3 EPS $(0.37) Misses $(0.30) Estimate
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 21.31 percent. This is a 61.86 percent increase over losses of $(0.97) per share from the
11-12 21:11
Annovis Bio Says All 84 Facilities For Pivotal Phase 3 Trial In Early Alzheimer's Disease Activated, First Group Of Patients Reaches 6-Month Treatment Milestone
Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's
11-06 21:08
Annovis launches $6 million registered direct offering
Annovis Bio (NYSE:ANVS) has entered into definitive agreements for the purchase of an aggregate of 4M shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.50 p...
10-10 20:58
Annovis Announces $6 Million Registered Direct Offering of Common Stock
Annovis Bio, a late-stage clinical company focused on neurodegenerative diseases, has entered into definitive agreements to purchase 4 million shares of its common stock at $1.50 per share in a registered direct offering, expected to close on October 13, 2025. The offering is being led by H.C. Wainwright & Co. as the exclusive placement agent and is expected to generate approximately $6 million in gross proceeds for the Company, which plans to us...
10-10 12:31
